mefloquine has been researched along with Benign Neoplasms, Brain in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, B; Wan, B; Wu, Z; Zhang, X | 1 |
| Aldape, KD; Alfred Yung, WK; Conrad, CA; de Groot, JF; Gilbert, MR; Groves, MD; Hess, KR; Loghin, ME; Mammoser, AG; Maraka, S; Melguizo-Gavilanes, I; O'Brien, BJ; Penas-Prado, M; Puduvalli, VK; Sulman, EP; Tremont-Lukats, IW | 1 |
| Geng, Y; Klocke, BJ; Kohli, L; Roth, KA | 1 |
1 trial(s) available for mefloquine and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Mefloquine; Memantine; Metformin; Middle Aged; Progression-Free Survival; Radiotherapy, Adjuvant; Research Design; Temozolomide; Treatment Outcome; Young Adult | 2019 |
2 other study(ies) available for mefloquine and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Mefloquine as a dual inhibitor of glioblastoma angiogenesis and glioblastoma via disrupting lysosomal function.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Male; Mefloquine; Mice, SCID; Neovascularization, Pathologic | 2021 |
Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent.
Topics: Antineoplastic Agents; Autophagy; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Chloroquine; Glioma; Humans; Immunohistochemistry; Mefloquine; Quinacrine; Tumor Suppressor Protein p53; Vacuoles | 2010 |